ClinicalTrials.gg
CompletedNCT04983264Updated Jun 10, 2024Results posted

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

A Phase 1 interventional study of GBT021601 in Sickle Cell Disease, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-06-10.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.

Enrollment
23rd of 27
6 · median 52
Started
2021
with 4 others
Phase 1
10 of 32
none open now
Registered
19th of 32
by date

Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 10 in phase 1, and was the 19th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Anemia, Sickle Cell by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK), and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in participants with SCD, following single and multiple ascending doses.

Read the detailed description

This is an open-label intrapatient single dose followed by a multiple dose escalation study in at least six (6) participants with SCD.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female with SCD
  • Participants with SCD ages 18 to 60 years, inclusive.
  • Participant has provided documented .
  • Patients with stable and close to baseline value
  • Patients on HU should be on stable dose for at least 90 days prior to signing ICF

Exclusion criteria

Exclusion Criteria:

  • Patients had more than 10 VOC within 12 months of screening
  • Patients who are pregnant or nursing
  • Patients who receive RBC transfusion therapy regularly or received an RBC transfusion for any reason within 60 days of signing the ICF
  • Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF or within 24 days prior to Day 1 treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Single-dose Period (Part A)

    Refer to Study Description

    Drug: GBT021601

  • Experimental
    Multiple Ascending-dose Period (Part B and Part C)

    Refer to Study Description

    Drug: GBT021601

Interventions

  • Tablets and capsules which contain GBT021601 drug substance

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment-emergent AE (TEAE) was an AE that occurs or worsens during the on-treatment period defined as the time from the first dose of study drug through minimum of 56 days after last dose of study treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening experience (immediate risk of death); required inpatient hospitalization or prolongation if existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; was considered an important medical event. TEAEs and SAEs were reported for both Sickle Cell Disease (SCD) and non-SCD related events, in this outcome measure.

    Time frame: From first dose of study drug (Day 1) to at least 56 days after last dose of study drug (up to a maximum of 316 days)

  2. Number of Participants With Clinically Significant Physical Examination Findings

    Physical examination included were general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.

    Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)

  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Laboratory parameters included hematology(hemoglobin,hematocrit,red blood cell count,platelet count,white blood cell count,total neutrophils,eosinophils,monocytes,basophils,lymphocytes);blood chemistry(blood urea,nitrogen, creatinine,glucose,calcium,sodium,potassium,chloride,total bicarbonate,aspartate aminotransferase,alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid albumin,total protein);urinalysis(decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood,ketones, microscopy\[urine tested positive for blood or protein\]),urine drug screening:cannabinoids,amphetamines,methamphetamines,opiates,methadone,cocaine,benzodiazepines,phencyclidine,barbiturates,alcohol breath test. Hemoximetry RBC deformability,dense cells test; erythropoietin,follicle stimulating hormone,pregnancy test,Serology panel for HIV 1/2 antibody,Hepatitis A, B and C,SARS CoV-2.Clinical significance of any parameter was determined at the investigator's discretion.

    Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs assessments included were systolic and diastolic blood pressure, heart rate, respiratory rate and body temperature. These measurements were taken after the participants had rested for at least 5 minutes in the supine position. Any clinically significant abnormal vital sign assessment required at least one repeat measurement. Clinical significance of any parameter was determined based on investigator's discretion.

    Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)

  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

    ECG values included here were Heart rate (HR), PR, QRS, QT, and QTcF intervals, interpretation of the tracings (eg, rhythm, presence of arrhythmia or conduction defects, any evidence of myocardial ischemia/infarction, or ST segment, T-wave, and U-wave abnormalities). Abnormal and clinically significant 12-lead ECG included QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 millisecond (ms), QRS interval \>= 120 ms, PR interval \> 220 ms, based on the average of triplicated ECG, assessed at Screening and Day-1. If any of these test results were out of range, then the test could be repeated once (in triplicate).

    Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)

Secondary outcomes

  1. Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  2. Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B

    Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.

    Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112

  3. Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C

    Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.

    Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28 and 42

  4. Minimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B

    Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.

    Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112

  5. Minimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C

    Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.

    Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28 and 42

  6. Time to Attain Maximum Serum Concentration (Tmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    Maximum observed concentration was defined as the peak concentration observed directly from the experimental data without any interpolation. The time to the maximum observed concentration was defined as the time corresponding to Cmax.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  7. Area Under the Concentration Time Curve From Time Zero to the Next Dose (AUC0-tau) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    AUC0-tau was defined from time 0 to time of the last quantifiable concentration and was calculated using the linear or logarithmic trapezoid rule. AUCtau was calculated by using hours\*microgram per milliliter (hr\*mcg)/mL.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  8. Area Under the Serum Concentration Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    AUCinf was defined as the area calculated by linear/log trapezoid rule from time 0 to infinity with the area extrapolated from the last quantifiable concentration to infinity.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  9. Area Under the Concentration Time Curve From Time Zero up to Time 24 Hours (AUC 0-24) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    AUC0-24 was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs post-dose on Day 1

  10. Apparent Oral Clearance (CL/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    CL/F was a quantitative measure of the rate at which a drug substance was removed from the blood. It was calculated as dose of GBT021601 by AUC from time 0 to infinity.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  11. Terminal Elimination Half-Life (t1/2) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    t1/2 was the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  12. Apparent Volume of Distribution (Vz/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was determined based on the fraction absorbed.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  13. Percentage Hemoglobin Occupancy

    Percentage hemoglobin occupancy (%Hb Occupancy) refers to the proportion of hemoglobin molecules within red blood cells that were bound to study drug (GBT021601). Cmin and Cmax values was used to calculate %Hb occupancy: %Hb Occupancy = GBT021601\*RBC per Mean Corpuscular Hemoglobin Concentration (MCHC).

    Time frame: Part A: Pre-dose,0.25,0.5,1,2,4, 6,8,12,24,36,48,72,168,336,504,672,1008 hrs on Day 1; Part B: Pre-dose,0.25 to 1,2 to 4 hrs post-dose on Day 56,63,70,77,84,91,98,105,112; Part C:Pre-dose on Day 1,14,28,42 and 0.25 to 1, 2 to 4 hrs post-dose on Day 28,42

  14. Plasma Concentrations Versus Time Summary of GBT021601: Part A

    The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  15. Plasma Concentrations Versus Time Summary of GBT021601: Part B

    The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.

    Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218

  16. Plasma Concentrations Versus Time Summary of GBT021601: Part C

    The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.

    Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98

  17. Whole Blood Concentrations Versus Time Summary of GBT021601: Part A

    The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  18. Whole Blood Concentrations Versus Time Summary of GBT021601: Part B

    The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.

    Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs, post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218

  19. Whole Blood Concentrations Versus Time Summary of GBT021601: Part C

    The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.

    Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98

  20. Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part A

    The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.

    Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1

  21. Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part B

    The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.

    Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218

  22. Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part C

    The RBC concentration versus time summary involved tracking a quantity of RBC in a sample of blood over a specified duration. This analysis helped to monitor RBC level over time.

    Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98

07

Results

Posted Jun 10, 2024

Participant flow

Part A: Single Dose Period
Participant flow — Part A: Single Dose Period
MilestonePart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Started600
Completed600
Not completed000
Part B: Multiple Dose Period
Participant flow — Part B: Multiple Dose Period
MilestonePart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Started060
Completed050
Not completed010
Withdrew: Physician decision010
Part C: Extended Treatment Period
Participant flow — Part C: Extended Treatment Period
MilestonePart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Started004
Completed003
Not completed001
Withdrew: Physician decision001

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment-emergent AE (TEAE) was an AE that occurs or worsens during the on-treatment period defined as the time from the first dose of study drug through minimum of 56 days after last dose of study treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening experience (immediate risk of death); required inpatient hospitalization or prolongation if existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; was considered an important medical event. TEAEs and SAEs were reported for both Sickle Cell Disease (SCD) and non-SCD related events, in this outcome measure.

Time frame:
From first dose of study drug (Day 1) to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
TEAEs: SCD Related131
SAEs: SCD Related020
TEAEs: Non-SCD Related553
SAEs: Non-SCD Related000
PrimaryNumber of Participants With Clinically Significant Physical Examination Findings

Physical examination included were general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.

Time frame:
Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Findings
ParticipantsPart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Number of Participants With Clinically Significant Physical Examination Findings000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

Laboratory parameters included hematology(hemoglobin,hematocrit,red blood cell count,platelet count,white blood cell count,total neutrophils,eosinophils,monocytes,basophils,lymphocytes);blood chemistry(blood urea,nitrogen, creatinine,glucose,calcium,sodium,potassium,chloride,total bicarbonate,aspartate aminotransferase,alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid albumin,total protein);urinalysis(decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood,ketones, microscopy\[urine tested positive for blood or protein\]),urine drug screening:cannabinoids,amphetamines,methamphetamines,opiates,methadone,cocaine,benzodiazepines,phencyclidine,barbiturates,alcohol breath test. Hemoximetry RBC deformability,dense cells test; erythropoietin,follicle stimulating hormone,pregnancy test,Serology panel for HIV 1/2 antibody,Hepatitis A, B and C,SARS CoV-2.Clinical significance of any parameter was determined at the investigator's discretion.

Time frame:
Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
ParticipantsPart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters100
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs assessments included were systolic and diastolic blood pressure, heart rate, respiratory rate and body temperature. These measurements were taken after the participants had rested for at least 5 minutes in the supine position. Any clinically significant abnormal vital sign assessment required at least one repeat measurement. Clinical significance of any parameter was determined based on investigator's discretion.

Time frame:
Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsPart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Number of Participants With Clinically Significant Change From Baseline in Vital Signs000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

ECG values included here were Heart rate (HR), PR, QRS, QT, and QTcF intervals, interpretation of the tracings (eg, rhythm, presence of arrhythmia or conduction defects, any evidence of myocardial ischemia/infarction, or ST segment, T-wave, and U-wave abnormalities). Abnormal and clinically significant 12-lead ECG included QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 millisecond (ms), QRS interval \>= 120 ms, PR interval \> 220 ms, based on the average of triplicated ECG, assessed at Screening and Day-1. If any of these test results were out of range, then the test could be repeated once (in triplicate).

Time frame:
Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
ParticipantsPart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)100
SecondaryMaximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Geometric mean · Microgram per milliliter (mcg/mL)
Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
Microgram per milliliter (mcg/mL)Part A: Single Dose Period
Plasma1.01 ± 20.81
Whole Blood16.2 ± 25.90
RBC concentration69.2 ± 28.63
SecondaryMaximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B

Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.

Time frame:
Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112
Reported as:
Geometric mean · mcg/mL
Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B
mcg/mLPart B: Multiple Ascending- Dose Period
Plasma- Day 562.46 ± 15.27
Plasma- Day 631.28 ± 18.54
Plasma- Day 701.54 ± 32.36
Plasma- Day 771.17 ± 22.44
Plasma- Day 841.17 ± 19.75
Plasma- Day 915.15 ± 19.32
Plasma- Day 982.77 ± 16.41
Plasma- Day 1052.96 ± 19.79
Plasma- Day 1123.22 ± 15.50
Whole Blood- Day 5640.9 ± 25.31
Whole Blood- Day 6385.5 ± 40.91
Whole Blood- Day 7080.3 ± 37.07
Whole Blood- Day 7787.1 ± 41.84
Whole Blood- Day 8489.1 ± 52.79
Whole Blood- Day 91136 ± 41.37
Whole Blood- Day 98201 ± 33.19
Whole Blood- Day 105194 ± 44.14
Whole Blood- Day 112200 ± 31.58
RBC concentration- Day 56169 ± 25.28
RBC concentration- Day 63366 ± 38.19
RBC concentration- Day 70309 ± 38.95
RBC concentration- Day 77337 ± 43.45
RBC concentration- Day 84345 ± 50.80
RBC concentration- Day 91522 ± 35.93
RBC concentration- Day 98788 ± 25.66
RBC concentration- Day 105748 ± 27.21
RBC concentration- Day 112670 ± 33.48
SecondaryMaximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C

Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.

Time frame:
Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28 and 42
Reported as:
Geometric mean · mcg/mL
Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C
mcg/mLPart C: Extended Treatment Period
Plasma - Day 282.66 ± 78.79
Plasma - Day 424.25 ± 81.86
Whole Blood - Day 28166 ± 126.31
Whole Blood - Day 42175 ± 141.04
RBC concentration - Day 28531 ± 105.76
RBC concentration - Day 42540 ± 125.43
SecondaryMinimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B

Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.

Time frame:
Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112
Reported as:
Geometric mean · mcg/mL
Minimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B
mcg/mLPart B: Multiple Ascending- Dose Period
Plasma- Day 630.97 ± 27.41
Plasma- Day 700.98 ± 22.18
Plasma- Day 770.90 ± 20.38
Plasma- Day 840.884 ± 21.58
Plasma- Day 910.90 ± 30.51
Plasma- Day 981.94 ± 24.77
Plasma- Day 1051.84 ± 27.55
Plasma- Day 1122.03 ± 24.43
Whole Blood- Day 6362.6 ± 42.01
Whole Blood- Day 7072.8 ± 36.26
Whole Blood- Day 7777.4 ± 45.27
Whole Blood- Day 8470.8 ± 67.54
Whole Blood- Day 9176.5 ± 49.02
Whole Blood- Day 98172 ± 43.11
Whole Blood- Day 105161 ± 45.00
Whole Blood- Day 112182 ± 31.55
RBC concentration- Day 63267 ± 41.68
RBC concentration- Day 70280 ± 38.56
RBC concentration- Day 77299 ± 46.55
RBC concentration- Day 84274 ± 65.32
RBC concentration- Day 91299 ± 43.50
RBC concentration- Day 98674 ± 34.28
RBC concentration- Day 105621 ± 26.23
RBC concentration- Day 112620 ± 34.72
SecondaryMinimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C

Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.

Time frame:
Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28 and 42
Reported as:
Geometric mean · mcg/mL
Minimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C
mcg/mLPart C: Extended Treatment Period
Plasma - Day 281.54 ± 220.43
Plasma - Day 421.99 ± 264.95
Whole Blood - Day 28122 ± 211.47
Whole Blood - Day 42140 ± 217.11
RBC concentration - Day 28392 ± 174.41
RBC concentration - Day 42433 ± 187.77
SecondaryTime to Attain Maximum Serum Concentration (Tmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

Maximum observed concentration was defined as the peak concentration observed directly from the experimental data without any interpolation. The time to the maximum observed concentration was defined as the time corresponding to Cmax.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Median · Hours
Time to Attain Maximum Serum Concentration (Tmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
HoursPart A: Single Dose Period
Plasma1.50 (1.00 to 2.02)
Whole Blood8.06 (6.00 to 35.92)
RBC concentration8.06 (6.00 to 35.92)
SecondaryArea Under the Concentration Time Curve From Time Zero to the Next Dose (AUC0-tau) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

AUC0-tau was defined from time 0 to time of the last quantifiable concentration and was calculated using the linear or logarithmic trapezoid rule. AUCtau was calculated by using hours\*microgram per milliliter (hr\*mcg)/mL.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Geometric mean · (hr*mcg)/mL
Area Under the Concentration Time Curve From Time Zero to the Next Dose (AUC0-tau) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
(hr*mcg)/mLPart A: Single Dose Period
Plasma67.102 ± 13.91
Whole Blood4597.8 ± 27.07
RBC concentration19627.6 ± 30.93
SecondaryArea Under the Serum Concentration Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

AUCinf was defined as the area calculated by linear/log trapezoid rule from time 0 to infinity with the area extrapolated from the last quantifiable concentration to infinity.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Geometric mean · (hr*mcg)/mL
Area Under the Serum Concentration Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
(hr*mcg)/mLPart A: Single Dose Period
Plasma72.03 ± 16.43
Whole Blood4914.50 ± 29.55
RBC concentration234.08 ± 13.95
SecondaryArea Under the Concentration Time Curve From Time Zero up to Time 24 Hours (AUC 0-24) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

AUC0-24 was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs post-dose on Day 1
Reported as:
Geometric mean · (hr*mcg)/mL
Area Under the Concentration Time Curve From Time Zero up to Time 24 Hours (AUC 0-24) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
(hr*mcg)/mLPart A: Single Dose Period
Plasma7.94 ± 12.11
Whole Blood322.0 ± 25.28
RBC concentration1363.3 ± 29.90
SecondaryApparent Oral Clearance (CL/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

CL/F was a quantitative measure of the rate at which a drug substance was removed from the blood. It was calculated as dose of GBT021601 by AUC from time 0 to infinity.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Geometric mean · Liter per hour
Apparent Oral Clearance (CL/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
Liter per hourPart A: Single Dose Period
Plasma1.39 ± 16.43
Whole Blood0.02 ± 29.55
RBC concentration0.004 ± 33.36
SecondaryTerminal Elimination Half-Life (t1/2) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

t1/2 was the time measured for the plasma concentration to decrease by one half.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Median · hr
Terminal Elimination Half-Life (t1/2) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
hrPart A: Single Dose Period
Plasma236.191 (187.44 to 313.49)
Whole Blood230.908 (207.80 to 303.05)
RBC concentration231.272 (206.58 to 302.82)
SecondaryApparent Volume of Distribution (Vz/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was determined based on the fraction absorbed.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
LiterPart A: Single Dose Period
Plasma480 ± 13.30
Whole Blood6.87 ± 22.56
RBC concentration1.61 ± 26.23
SecondaryPercentage Hemoglobin Occupancy

Percentage hemoglobin occupancy (%Hb Occupancy) refers to the proportion of hemoglobin molecules within red blood cells that were bound to study drug (GBT021601). Cmin and Cmax values was used to calculate %Hb occupancy: %Hb Occupancy = GBT021601\*RBC per Mean Corpuscular Hemoglobin Concentration (MCHC).

Time frame:
Part A: Pre-dose,0.25,0.5,1,2,4, 6,8,12,24,36,48,72,168,336,504,672,1008 hrs on Day 1; Part B: Pre-dose,0.25 to 1,2 to 4 hrs post-dose on Day 56,63,70,77,84,91,98,105,112; Part C:Pre-dose on Day 1,14,28,42 and 0.25 to 1, 2 to 4 hrs post-dose on Day 28,42
Reported as:
Mean · Percentage of Hemoglobin
Percentage Hemoglobin Occupancy
Percentage of HemoglobinPart A: Single Dose PeriodPart B: Multiple Ascending- Dose PeriodPart C: Extended Treatment Period
Part A: Cmax- Day 13.36 ± 0.86——
Part B: Cmax- Day 56—8.15 ± 1.89—
Part B: Cmax - Day 63—18.15 ± 5.96—
Part B: Cmin- Day 63—13.40 ± 4.71—
Part B: Cmax- Day 70—15.50 ± 5.11—
Part B: Cmin- Day 70—14.03 ± 4.69—
Part B: Cmax- Day 77—17.03 ± 6.00—
Part B: Cmin- Day 77—15.25 ± 5.54—
Part B: Cmax- Day 84—17.66 ± 7.75—
Part B: Cmin- Day 84—14.57 ± 7.29—
Part B: Cmax- Day 91—25.71 ± 7.92—
Part B: Cmin- Day 91—15.02 ± 5.85—
Part B: Cmax- Day 98—38.00 ± 9.05—
Part B: Cmin- Day 98—33.04 ± 9.31—
Part B: Cmax- Day 105—36.11 ± 9.14—
Part B: Cmin- Day 105—29.89 ± 7.21—
Part B: Cmax- Day 112—32.68 ± 9.33—
Part B: Cmin- Day 112—30.32 ± 8.92—
Part C: Cmax- Day 28——31.45 ± 17.97
Part C: Cmin- Day 28——26.54 ± 16.96
Part C: Cmax- Day 42——33.13 ± 19.12
Part C: Cmin- Day 42——29.46 ± 18.09
SecondaryPlasma Concentrations Versus Time Summary of GBT021601: Part A

The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Mean · mcg/mL
Plasma Concentrations Versus Time Summary of GBT021601: Part A
mcg/mLPart A: Single Dose Period
Pre-dose0 ± 0
0.25 hour0.145 ± 0.137
0.5 hour0.617 ± 0.281
1 hour0.910 ± 0.312
2 hours0.821 ± 0.202
4 hours0.498 ± 0.150
6 hours0.350 ± 0.100
8 hours0.279 ± 0.737
12 hours0.228 ± 0.040
24 hours0.257 ± 0.120
36 hours0.333 ± 0.286
48 hours0.183 ± 0.067
72 hours0.138 ± 0.019
168 hours0.124 ± 0.020
336 hours0.0786 ± 0.016
504 hours0.047 ± 0.016
672 hours0.029 ± 0.137
1008 hours0.013 ± 0.007
SecondaryPlasma Concentrations Versus Time Summary of GBT021601: Part B

The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.

Time frame:
Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218
Reported as:
Mean · mcg/mL
Plasma Concentrations Versus Time Summary of GBT021601: Part B
mcg/mLPart B: Multiple Ascending- Dose Period
Day 56: Pre-dose0.143 ± 0.351
Day 56 :0.25-1 hour1.163 ± 1.165
Day 56: 2-4 hours2.345 ± 0.3129
Day 63: Pre-dose1.015 ± 0.240
Day 63: 0.25-1 hour1.148 ± 0.268
Day 63: 2-4 hours1.250 ± 0.210
Day 70: Pre-dose1.003 ± 0.211
Day 70: 0.25-1 hour1.376 ± 0.653
Day 70: 2-4 hours1.415 ± 0.262
Day 77: Pre-dose0.937 ± 0.151
Day 77: 0.25-1 hour1.103 ± 0.318
Day 77: 2-4 hours1.173 ± 0.233
Day 84: Pre-dose0.918 ± 0.176
Day 84 :0.25-1 hour1.085 ± 0.284
Day 84: 2-4 hours1.097 ± 0.205
Day 91: Pre-dose0.941 ± 0.278
Day 91; 0.25-1 hour3.019 ± 2.225
Day 91: 2-4 hours4.990 ± 0.635
Day 98: Pre-dose2.118 ± 0.687
Day 98: 0.25-1 hour2.242 ± 0.398
Day 98: 2-4 hours2.580 ± 0.53933
Day 105: Pre-dose1.945 ± 0.570
Day 105: 0.25-1 hour2.147 ± 0.470
Day 105: 2-4 hours2.953 ± 0.642
Day 112 :Predose2.095 ± 0.242
Day 112: 0.25-1 hour2.748 ± 0.824
Day 112: 2-4 hours2.905 ± 0.688
Day 140: 2-4 hours0.225 ± 0.0516
Day 168: 2-4 hours0.042 ± 0.026
Day 196: 2-4 hours0.005 ± 0.005
Day 218: 2-4 hours0.000 ± 0.001
SecondaryPlasma Concentrations Versus Time Summary of GBT021601: Part C

The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.

Time frame:
Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98
Reported as:
Mean · mcg/mL
Plasma Concentrations Versus Time Summary of GBT021601: Part C
mcg/mLPart C: Extended Treatment Period
Day 28: Pre-dose2.448 ± 1.786
Day 28: 4 hours2.991 ± 1.476
Day 42: Pre-dose3.621 ± 2.929
Day 42: 0.25-1 hour4.285 ± 2.785
Day 42: 2-4 hours4.485 ± 2.308
Day 70: 2-4 hours0.364 ± 0.101
Day 98: 2-4 hours0.034 ± 0.011
SecondaryWhole Blood Concentrations Versus Time Summary of GBT021601: Part A

The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Mean · mcg/mL
Whole Blood Concentrations Versus Time Summary of GBT021601: Part A
mcg/mLPart A: Single Dose Period
Pre-dose0 ± 0
0.25 hour1.034 ± 0.876
0.5 hour4.775 ± 2.470
1 hour8.745 ± 3.833
2 hours12.710 ± 3.190
4 hours14.07 ± 2.917
6 hours14.44 ± 2.980
8 hours14.42 ± 2.861
12 hours14.45 ± 3.811
24 hours14.42 ± 3.220
36 hours15.41 ± 4.220
48 hours13.14 ± 2.895
72 hours12.42 ± 3.193
168 hours9.847 ± 2.562
336 hours5.282 ± 1.283
504 hours3.870 ± 1.071
672 hours2.138 ± 1.283
1008 hours0.943 ± 0.729
SecondaryWhole Blood Concentrations Versus Time Summary of GBT021601: Part B

The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.

Time frame:
Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs, post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218
Reported as:
Mean · mcg/mL
Whole Blood Concentrations Versus Time Summary of GBT021601: Part B
mcg/mLPart B: Multiple Ascending- Dose Period
Day 56: Pre-dose0.071 ± 0.085
Day 56: 0.25-1 hour13.20 ± 13.601
Day 56: 2-4 hours41.23 ± 10.318
Day 63: Pre-dose74.32 ± 30.266
Day 63: 0.25-1 hour88.23 ± 33.335
Day 63: 2- 4 hours74.87 ± 19.748
Day 70: Pre-dose78.28 ± 24.403
Day 70: 0.25-1 hour81.00 ± 22.709
Day 70: 2-4 hours81.25 ± 25.669
Day 77: Pre-dose86.22 ± 30.703
Day 77: 0.25-1 hour87.33 ± 27.507
Day 77: 2- 4 hours88.68 ± 29.043
Day 84: Predose87.77 ± 43.076
Day 84 :0.25-1 hour88.97 ± 42.685
Day 84: 2-4 hours92.05 ± 36.530
Day 91: Pre-dose85.07 ± 32.859
Day 91; 0.25-1 hour102.4 ± 52.161
Day 91: 2-4 hours144.1 ± 47.113
Day 98: Pre-dose195.8 ± 61.979
Day 98: 0.25-1 hour188.8 ± 61.802
Day 98: 2-4 hours198.8 ± 49.301
Day 105: Pre-dose189.8 ± 56.672
Day 105: 0.25-1 hour178.9 ± 66.612
Day 105: 2-4 hours203.3 ± 74.923
Day 112: Pre-dose195.0 ± 59.117
Day 112: 0.25-1 hour200.5 ± 57.263
Day 112: 2-4 hours198.5 ± 59.248
Day 140: 2-4 hours29.32 ± 20.149
Day 168: 2-4 hours3.082 ± 2.137
Day 196: 2-4 hours0.561 ± 0.560
Day 218: 2-4 hours0.108 ± 0.109
SecondaryWhole Blood Concentrations Versus Time Summary of GBT021601: Part C

The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.

Time frame:
Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98
Reported as:
Mean · mcg/mL
Whole Blood Concentrations Versus Time Summary of GBT021601: Part C
mcg/mLPart C: Extended Treatment Period
Day 28: Pre-dose202.2 ± 136.32
Day 28: 4 hours193.6 ± 106.16
Day 42: Pre-dose214.8 ± 131.21
Day 42: 0.25-1 hour213.5 ± 119.79
Day 42: 2- 4 hours229.9 ± 132.21
Day 70: 2-4 hours33.50 ± 2.553
Day 98: 2-4 hours3.310 ± 0.826
SecondaryRed Blood Cell Concentrations Versus Time Summary of GBT021601: Part A

The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.

Time frame:
Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Reported as:
Mean · mcg/mL
Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part A
mcg/mLPart A: Single Dose Period
Pre-dose0 ± 0
0.25 hour3.989 ± 3.314
0.5 hour18.68 ± 10.413
1 hour34.84 ± 16.282
2 hours52.51 ± 14.931
4 hours59.50 ± 14.281
6 hours61.72 ± 15.356
8 hours61.68 ± 13.932
12 hours62.24 ± 18.340
24 hours61.92 ± 16.283
36 hours65.62 ± 18.780
48 hours56.60 ± 14.463
72 hours53.68 ± 15.728
168 hours42.41 ± 12.260
336 hours22.73 ± 6.316
504 hours16.65 ± 4.931
672 hours9.207 ± 5.652
1008 hours4.073 ± 3.186
SecondaryRed Blood Cell Concentrations Versus Time Summary of GBT021601: Part B

The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.

Time frame:
Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218
Reported as:
Mean · mcg/mL
Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part B
mcg/mLPart B: Multiple Ascending- Dose Period
Day 56: Pre-dose0.120 ± 0.134
Day 56 :0.25-1 hour52.57 ± 53.388
Day 56: 2-4 hours170.8 ± 45.616
Day 63: Pre-dose317.4 ± 126.93
Day 63: 0.25-1 hour375.4 ± 134.89
Day 63: 2-4 hours318.6 ± 83.313
Day 70: Pre-dose304.7 ± 105.71
Day 70: 0.25-1 hour313.9 ± 97.320
Day 70: 2-4 hours314.7 ± 106.95
Day 77: Pre-dose335.9 ± 130.15
Day 77: 0.25-1 hour340.1 ± 118.67
Day 77: 2-4 hours343.8 ± 120.89
Day 84: Pre-dose338.6 ± 169.41
Day 84 :0.25-1 hour344.7 ± 170.26
Day 84: 2-4 hours356.0 ± 144.12
Day 91: Pre-dose329.0 ± 124.33
Day 91; 0.25-1 hour392.6 ± 197.92
Day 91: 2-4 hours547.7 ± 173.83
Day 98: Pre-dose753.5 ± 207.85
Day 98: 0.25-1 hour726.2 ± 215.42
Day 98: 2-4 hours768.9 ± 164.84
Day 105: Pre-dose711.7 ± 148.81
Day 105: 0.25-1 hour662.4 ± 190.38
Day 105: 2-4 hours752.8 ± 222.08
Day 112: Predose705.6 ± 209.26
Day 112: 0.25-1 hour674.3 ± 201.56
Day 112: 2-4 hours666.7 ± 206.56
Day 140: 2-4 hours120.8 ± 83.588
Day 168: 2-4 hours14.97 ± 9.339
Day 196: 2-4 hours2.326 ± 2.226
Day 218: 2-4 hours0.850 ± 0.539
SecondaryRed Blood Cell Concentrations Versus Time Summary of GBT021601: Part C

The RBC concentration versus time summary involved tracking a quantity of RBC in a sample of blood over a specified duration. This analysis helped to monitor RBC level over time.

Time frame:
Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98
Reported as:
Mean · mcg/mL
Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part C
mcg/mLPart C: Extended Treatment Period
Day 28: Pre-dose621.3 ± 428.95
Day 28: 4 hours594.4 ± 319.62
Day 42: Pre-dose642.4 ± 396.97
Day 42: 0.25-1 hour639.8 ± 361.11
Day 42: 2-4 hours691.1 ± 404.73
Day 70: 2-4 hours117.9 ± 20.028
Day 98: 2-4 hours12.74 ± 3.256

Adverse events

Collected over From baseline (Day 1) up to at least 56 days after last dose of study drug (for a maximum of 316 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Single Dose Period (SCD Related)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part B: Multiple Ascending- Dose Period (SCD Related)0/6 (0%)2/6 (33.3%)2/6 (33.3%)
Part C: Extended Treatment Period (SCD Related)0/4 (0%)0/4 (0%)1/4 (25%)
Part A: Single Dose Period (Non-SCD Related)0/6 (0%)0/6 (0%)5/6 (83.3%)
Part B: Multiple Ascending- Dose Period (Non-SCD Related)0/6 (0%)0/6 (0%)5/6 (83.3%)
Part C: Extended Treatment Period (Non-SCD Related)0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventPart A: Single Dose Period (SCD Related)Part B: Multiple Ascending- Dose Period (SCD Related)Part C: Extended Treatment Period (SCD Related)Part A: Single Dose Period (Non-SCD Related)Part B: Multiple Ascending- Dose Period (Non-SCD Related)Part C: Extended Treatment Period (Non-SCD Related)
Sickle cell anaemia with crisisBlood and lymphatic system disorders0/62/60/40/60/60/4
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPart A: Single Dose Period (SCD Related)Part B: Multiple Ascending- Dose Period (SCD Related)Part C: Extended Treatment Period (SCD Related)Part A: Single Dose Period (Non-SCD Related)Part B: Multiple Ascending- Dose Period (Non-SCD Related)Part C: Extended Treatment Period (Non-SCD Related)
NeutropeniaBlood and lymphatic system disorders0/60/60/40/62/60/4
DiarrhoeaGastrointestinal disorders0/60/60/40/62/60/4
Sickle cell anaemia with crisisBlood and lymphatic system disorders1/62/61/40/60/60/4
Abdominal painGastrointestinal disorders0/60/60/40/60/61/4
ArthralgiaMusculoskeletal and connective tissue disorders0/60/60/40/61/61/4
Back painMusculoskeletal and connective tissue disorders0/60/60/40/60/61/4
Pain in extremityMusculoskeletal and connective tissue disorders0/60/60/40/60/61/4
HeadacheNervous system disorders0/60/60/41/60/61/4
AnaemiaBlood and lymphatic system disorders0/60/60/40/61/60/4
ThrombocytosisBlood and lymphatic system disorders0/60/60/41/60/60/4

Baseline characteristics

Safety population was defined as all participants who received any amount of study drug (GBT021601).

Age, Continuous
Age, Continuous(Years)Overall Study
Mean20.2 ± 2.23
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female2
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino1
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White0
More than one race0
Unknown or Not Reported1
08

Study locations

3 sites
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Visionaries Clinical Research LLC
    Atlanta, Georgia 30329, United States
  • Children's Healthcare of Atlanta AFLAC Center
    Atlanta, Georgia 30342, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2022, 18 months.

Results were first posted in Jun 2024, 1 year 6 months after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 18 months is below that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jul 30, 2021
StartActual
May 21, 2021
Primary completionActual
Dec 6, 2022
CompletionActual
Dec 6, 2022
Results first posted
Jun 10, 2024
Last update
Jun 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04983264
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
May 21, 2021
Primary completion
Dec 6, 2022
Completion
Dec 6, 2022
Results posted
Jun 10, 2024
Last update
Jun 10, 2024

Study contacts

Pfizer Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osivelotor

Start the discussion